Literature DB >> 17729056

Does elevated high-sensitivity serum C-reactive protein associate with hypertension in non-obese Japanese males?

Takuya Imatoh1, Motonobu Miyazaki, Hiroshi Une.   

Abstract

The object of this study is to assess whether elevated hsCRP levels are independently related to hypertension in non-obese Japanese males. This cross-sectional study comprised 86 hypertensive and 109 normotensive subjects. We defined hypertension as a systolic blood pressure >/=140 mmHg and/or a diastolic blood pressure >/=90 mmHg and/or taking antihypertensive therapy. Log-hsCRP levels were significantly higher in hypertensive than normotensive subjects. In logistic regression analysis, subjects in the highest tertile had a two-fold higher risk than those in the lowest tertile. The association between hypertension and hsCRP levels was marginally significant. In addition, there was a significant tendency for hypertension to increase with an increase in CRP level (p < .05). These findings suggest that elevated hsCRP level is an independent risk factor for hypertension in non-obese Japanese males.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17729056     DOI: 10.1080/10641960701578394

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  2 in total

1.  The effect of aerobic versus strength-based training on high-sensitivity C-reactive protein in older adults.

Authors:  Raul A Martins; Ana P Neves; Manuel J Coelho-Silva; Manuel T Veríssimo; Ana Maria Teixeira
Journal:  Eur J Appl Physiol       Date:  2010-05-01       Impact factor: 3.078

2.  Effects of serum homocysteine and adiponectin levels on platelet aggregation in untreated patients with essential hypertension.

Authors:  Hakan Ekmekçi; Ozlem Balci Ekmekçi; Serap Erdine; Hüseyin Sönmez; Yusup Ataev; Zeynep Oztürk; Ilknur Işler Bütün; Ciğdem Gürel; Mine Kucur; Nurver Turfaner; Turgut Ulutin; Sevim Purisa; Vural Ali Vural
Journal:  J Thromb Thrombolysis       Date:  2008-11-11       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.